Immupharma (IMM)

 

IMM Share PerformanceMore

52 week high102.10 09/10/17
52 week low31.44 09/11/16
52 week change 52.88 (140.07%)
4 week volume12,757,897 20/09/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 7306T Immupharma PLC 16 October 2017 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma Plc 213800VZKGHXC7VUS895 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK iss...

ImmuPharma completes sharing agreement with Lanstead

ImmuPharma has announced the completion of the sharing agreement entered into with Lanstead Capital in February 20...

Completion of Lanstead Sharing Agreement

RNS Number: 6150S Immupharma PLC 04 October 2017 4 OCTOBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Completion of Lanstead Sharing Agreement ImmuPharma plc (LSE: IMM), the specialist drug discovery and development company , wishes to announce the completion of the Sharing Agreement entered into with Lanstead Capital L....

ImmuPharma revenues rise

ImmuPharma's operating losses narrowed slightly in the six months to end of June falling to 3,186,951 from 3,239,547. Reven...

Interim Results

RNS Number: 8856R Immupharma PLC 27 September 2017 FOR IMMEDIATE RELEASE 27 SEPTEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2017 ImmuPharma PLC (LSE:IMM) , ("ImmuPharma" or the "Company"), the specialist drug discovery and develo...

Preparation of Lupuzor'sT Regulatory Submissions

RNS Number: 7616R Immupharma PLC 26 September 2017 RNS: FOR IMMEDIATE RELEASE 26 September 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") ImmuPharma initiates preparation of Lupuzor's regulatory submissions ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to confirm a furthe...

Update on LupuzorT Pivotal Phase III Study

RNS Number: 3535R Immupharma PLC 21 September 2017 21 September 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...

ImmuPharma schedules interims

ImmuPharma, the specialist drug discovery and development company, has confirmed that it would announce its results f...

Fundamental DataMore

EPS-4.54
Dividend yield0 %

Latest discussion posts More

  • Re: 9.5% rise...

    That was a lucky top up over 100% gain @ #1 / :-)
    9-Oct-2017
    Ripley94
  • Re: 100p now.. wow

    Nice to Michu - interesting that you have sold some of your holding. I am keeping all mine that I have accumulated over many years at an average of 62P. This is the first time ...
    9-Oct-2017
    Chrissp
  • 100p now.. wow

    maybe it's buy and hold institutional money coming in here.. I sold another 10% at 100p just now.. maybe I shouldnt be selling at all .. only time will tell .. still have a ...
    9-Oct-2017
    Nice to Michu

Users' HoldingsMore

Users who hold Immupharma also hold..
LLOYDS GRP.28%
BP20%
SIRIUS MINERALS14%
NATIONAL GRID13%
LEGAL&GEN.12%

Codes & Symbols

ISINGB0033711010
SymbolsIMM, LSE:IMM, IMM.L, IMM:LN, LON:IMM, XLON:IMM